ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / NDRA / forecast
IRIX (27) ITOC (33) NUWE (33) NXL (32) ⌘ Pro Terminal →

ENDRA Life Sciences Inc. (NDRA) 12-Month Stock Forecast & Price Target Cone

$4.80 +1.05% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $4.80

ENDRA Life Sciences Inc. (NDRA) carries a Roarable Rating of D- (Sell) with 36/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $7.1M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on NDRA Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is NDRA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, ENDRA Life Sciences Inc. (NASDAQ: NDRA) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $4.80 (+1.05% 1D, market cap $7.1M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, NDRA ranks #581 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does NDRA compare to IRIX and ITOC in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), NDRA carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, IRIX (IRIDEX Corporation) holds a E grade (27/100 RQD, P/E N/A, ROIC -35.0%, cap $12.5M) and ITOC (iTonic Holdings Ltd (Class A)) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $19.0M). Among the 5-stock peer group, NDRA leads on earnings multiple (N/A) while NDRA leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for NDRA?
▼

Per NDRA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001681682), ENDRA Life Sciences Inc. generated $16.1M in revenue (-46.7% YoY), -$7.0M in net income, and -$5.2M in free cash flow against $3.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $4.80 (+0.00%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (36/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.3% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • D-
025507510036
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk D
Cash (6)Whales (5)SEC (10)Macro (10)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-10% Base Target
$7 Bull$4 Base$3 Bear
📬 FREE NDRA RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NDRA)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (36/100 Composite)
🔍 WHY NDRA SCORES 36/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (28% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (28% of score)

FRED Regime × Technicals: 46% of 52W Range • RSI-14 at 42.7 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
44
Grade D$5.04-11.3% Next Q
Q2 (-2Q)
41
Grade D$4.47+11% Next Q
Q3 (-1Q)
39
Grade E$4.96-3.2% Next Q
Current
36
Grade D-$4.80-8.3% Hist 90D α
Trajectory: D (44) → D- (36)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a NDRA Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While NDRA currently carries a cautious 36/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($5.45) and Max Pain ($5.04) forces dealer call-delta covering toward $7.30.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $NDRA• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “NDRA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 36%NO 64%Trade / Inspect Odds →
INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your NDRA Position Size: $10,000

Shares at $4.80: 2083.3 sh
$1,000$10,000$25,000$50,000$100,000
12M Bear Case FloorTarget $3.37
$7,021
$-2,979 (-29.8%)
12M Consensus BaseTarget $4.32
$9,000
$-1,000 (-10.0%)
12M Bull Case BreakoutTarget $7.30
$15,208
+$5,208 (+52.1%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100
● Strong Buy / Buy: 17● Hold: 9● Sell: 9
Wall Street FirmStance12M Target1Y AccuracyTrack Grade
Morgan StanleyInstitutional Equity DeskHOLD$474%A
Goldman SachsSector Coverage LeadUNDERPERFORM$769%B
JP MorganUS Large-Cap ResearchSELL$458%C
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NDRA)

  • ✓Walkthrough of NDRA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
NDRA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -2.83%📐 HORIZONTAL RANGE
2026-11-03O $4.88H $4.88L $4.75C $4.80VOL 10.6K
RES: $6.82SUP: $4.30SMA50: $5.45SMA200: $4.81
$6.97$6.06$5.14$4.23$3.32RES $6.82SUP $4.30$4.802026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NDRA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 NDRA Butterfly Map → + Track NDRA →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -46.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on NDRA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for NDRA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for NDRA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NDRA)

Health Care Rank #581 of 1015 ⚔️ IRIX vs NDRA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (NDRA vs. IRIX, ITOC, NUWE, NXL)

Industry: Biotechnology: Electromedical & Electrotherapeutic Apparatus (26 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, ENDRA Life Sciences Inc. (NDRA) ranks #581 by composite RQD confidence (36/100, grade D-) and #918 by equity capitalization ($7.1M). Within this direct 5-issuer industry benchmark cohort, NDRA leads on earnings valuation at N/A trailing P/E, while NDRA leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. NDRA currently leads its immediate peer cohort in composite quantitative strength at 36/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
NDRA ACTIVE
ENDRA Life Sciences Inc.
D- 36/100 — — -35.0% +1.05% $7.1M Benchmark Subject
IRIX
IRIDEX Corporation
E 27/100 — 36.5% -35.0% +1.33% $12.5M /irix-vs-ndra →
ITOC
iTonic Holdings Ltd (Class A)
E 33/100 — 62.6% -35.0% -9.61% $19.0M /itoc-vs-ndra →
NUWE
Nuwellis Inc.
E 33/100 — 62.0% -35.0% -8.80% $2.3M /nuwe-vs-ndra →
NXL
Nexalin Technology Inc.
E 32/100 — 79.7% -35.0% -5.94% $1.8M /nxl-vs-ndra →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001681682 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), ENDRA Life Sciences Inc. (NDRA) reported GAAP revenue of $16.1M (-46.7% vs. FY2024 revenue of $30.3M , and -45.2% cumulative change since FY2023) , GAAP net income of -$7.0M, operating cash flow of -$5.2M, and free cash flow of -$5.2M (+29.9% YoY). On the balance sheet, NDRA closed FY2025 with $3.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $16.1M -$7.0M -$5.2M -$5.2M $3.9M —
FY2024 (FY) 2024-12-31 $30.3M -$11.5M -$7.4M -$7.4M $4.5M —
FY2023 (FY) 2023-12-31 $29.5M -$10.1M -$9.5M -$9.5M — —

3. NDRA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NDRA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, ENDRA Life Sciences Inc. (NASDAQ: NDRA) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $4.80 (+1.05% 1D, market cap $7.1M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, NDRA ranks #581 in composite RQD confidence.

How does NDRA compare to IRIX and ITOC in the Health Care sector?

Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), NDRA carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, IRIX (IRIDEX Corporation) holds a E grade (27/100 RQD, P/E N/A, ROIC -35.0%, cap $12.5M) and ITOC (iTonic Holdings Ltd (Class A)) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $19.0M). Among the 5-stock peer group, NDRA leads on earnings multiple (N/A) while NDRA leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for NDRA?

Per NDRA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001681682), ENDRA Life Sciences Inc. generated $16.1M in revenue (-46.7% YoY), -$7.0M in net income, and -$5.2M in free cash flow against $3.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is NDRA trading relative to its 50-day, 200-day, and 52-week technical levels?

NDRA last traded at $4.80 (+1.05% on volume of 5,797 shares), positioning the stock -11.93% below its 50-day simple moving average ($5.45) and -0.21% below its 200-day simple moving average ($4.81). Across its 52-week range of $2.96 to $6.95, NDRA sits at the 46.1% percentile with a 14-day RSI of 42.7 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($4.20 to $5.40).

Direct Sub-Reports: NDRA RQD Cockpit NDRA 12M Forecast NDRA Earnings & Move NDRA Dividends & DRIP NDRA Insiders & 13F NDRA Whale Options NDRA Profit Sankey NDRA News & Why
ROARABLE RATING BRIEF • RQD 36/100 (D-) ✓ SEC XBRL & RQD VERIFIED

NDRA — ENDRA Life Sciences Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

ENDRA Life Sciences Inc. (NDRA) earns a live Roarable RQD composite score of 36/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $4.80 (+1.05% 1D, market capitalization $7.1M).

  • Fundamental Cash Engine (6/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (5/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (10/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 3/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

ENDRA Life Sciences Inc. (NDRA) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry. It carries a market capitalization of $0.0B, which is inconsistent with the $7.3M figure in market data and should be treated with caution. — describes its specific products, customers, or revenue model. Reported revenue is — in each listed period.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), ENDRA Life Sciences Inc. (NDRA) reported $16.1M in annual revenue (up from $30.3M in FY2024, -46.7% YoY) and -$7.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($29.5M revenue, -$10.1M net income) through FY2025, NDRA scaled operating cash flow to -$5.2M and free cash flow to -$5.2M, backed by $3.9M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D- • RQD 36/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 5/20. With Fundamental Cash Engine at 6/20 and Institutional Whale Flow at 5/20, sustained execution supports upside toward the upper end of the $2.96 – $6.95 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

A prospective investor should note that the absence of mapped links means this dossier cannot identify which suppliers, customers, or sector peers would transmit shocks to NDRA.

  • Key Question #1: Can NDRA sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Electromedical & Electrotherapeutic Apparatus peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $16.1M and free cash flow of -$5.2M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is NDRA's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

NDRA Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for ENDRA Life Sciences Inc. (NDRA) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to NDRA Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

NDRA Bull vs. Bear Conversation Board — What's Your Call at $4.80?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON NDRA 🐻 33% BEARISH CONVICTION
1. Pick Your Side on NDRA:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
CA CashFlowKing RQD DEBATE OPENER • FCF Compounder Hunter 🐂 BULLISH 🎯 Target: $5.89 (+24.0%)
📌 Pinned Debate

The stock trades at $4.88 with a 52-week range of $2.96 - $6.95 and a 2.95% daily gain, with a GREEN-flagged catalyst item in the news

Here is why I am bullish on NDRA here at $4.75: The stock trades at $4.88 with a 52-week range of $2.96 - $6.95 and a 2.95% daily gain, with a GREEN-flagged catalyst item in the news feed.. Compare NDRA's 0.0% operating margin and -35.0% ROIC against the rest of Biotechnology: Electromedical & Electrotherapeutic Apparatus. As long as cash conversion holds up, dips toward $4.51 are getting bought.

VolSurface_Trader 🐂 BULL

@FadeTheHype Shorting a 5/20 institutional whale-flow stock at $4.75 is dangerous when funds are rotating into Health Care.

FA FadeTheHype RQD DEBATE OPENER • Contrarian Tape Reader 🐻 BEARISH 🎯 Target: $3.75 (-21.1%)
Spot @ $4.75

The company reports zero revenue, negative FCF in every period, ROIC of -35%, and cash falling from $3.2M to $0.8M, with an RQD score o

The company reports zero revenue, negative FCF in every period, ROIC of -35%, and cash falling from $3.2M to $0.8M, with an RQD score of 42.. Look at the math on NDRA: paying current EV/EBITDA multiples for -35.0% ROIC and 0.0% operating margins leaves zero margin of safety if Biotechnology: Electromedical & Electrotherapeutic Apparatus demand softens. I'd wait for a retest of $4.18 before getting long.

LIVE TAPE